Economía de la Salud


Opciones: Vista Forum

Use Monospaced Font
Por defecto enseñar Text Part
Esconda cabeceras de correo

Mensaje: [<< Primero] [< Prev] [Siguiente >] [Último >>]
Tema: [<< Primero] [< Prev] [Siguiente >] [Último >>]
Autor: [<< Primero] [< Prev] [Siguiente >] [Último >>]

Print Responder
by LISTSERV.REDIRIS.ES (LISTSERV-TCP/IP release 16.0) with spool id 12452112 for [log in para visualizar]; Wed, 22 Jul 2020 18:53:02 +0200 from ( []) by (Postfix) with ESMTP id D03AC233CE; Wed, 22 Jul 2020 18:53:02 +0200 (CEST)
text/plain; charset="utf-8"
Wed, 22 Jul 2020 18:53:02 +0200
Economía de la Salud <[log in para visualizar]>
AES ECONSALUD <[log in para visualizar]>
Economía de la Salud <[log in para visualizar]>
text/plain (98 lines)
We are pleased to announce the opening of registration for our online R for Health Technology Assessment (HTA) showcase taking place on the 13:00-17:00 BST 9th October and 9:00-13:00 BST 12th October. Speakers from academia, government, industry, and consulting will give demonstrations of their R code solving specific challenges in HTA, ranging from patient level simulation and infectious disease modelling to propensity score weighting and expert elicitation. On 12th October 12:00-13:00 BST there will be a panel discussion on the value and challenges of using R in HTA, with Francois Maignen (NICE), Andrew Briggs (LSHTM), Liz Fenwick (Pharmerit), and Venediktos Kapetanakis (Evidera).

Registration is free and can be complete at this link:

Note that you must register separately for each of the half-day events.


Day 1. Showcase. Friday 9th October 2020.

13:00-13:10. Howard Thom, University of Bristol.


13:10-13:40. Joe Moss, York Health Economics Consortium

An introduction to programming a patient level simulation (PLS) in R

13:40-14:05. Kevin Deighton, DeltaHat.

Propensity scores in R. Managing multiple scenario analyses in a single clean script.

14:05-14:20. Break

14:20-14:45. Josephine Walker, University of Bristol.

Using R for cost-effectiveness analysis of Hepatitis C screening and treatment interventions in low and middle-income countries

14:45-15:10. Devin Incerti, Genentech Inc

Multistate Semi-Markov modelling in R

15:10-15:35. Claire Simons. Pharmerit.

A novel approach to modelling treatment sequences: implementation and challenges.

15:35-15:50 Break

15:50-16:15. Mi Jun Keng, University of Oxford.

Optimizing a Markov model using apply, parallel computing, and Rcpp.

16:15-16:30. Iryna Schlackow, University of Oxford.

The Tidyverse style guide.

16:30-16:55. Seamus Kent, University of Oxford.

Generating evidence for HTA using the OMOP common data model and standardised analytical tools

16:55-17:00. Gianluca Baio.

Closing remarks.
Day 2. Showcase. Monday 12th October 2020.

9:00-9:10. Howard Thom, University of Bristol.


9:10-9:35. Sam Abbott, London School of Hygiene and Tropical Medicine.

The SpeedyMarkov package. A highly optimized package for cohort Markov models in R.

9:35-10:00. Yiqiao Xin, University of Glasgow.

From spreadsheets to script: converting the Scottish cardiovascular disease policy model into R

10:00-10:15 Break

10:15-10:40. Philip Cooney. Novartis Pharma.

Incorporating clinical opinion into survival extrapolations with visualisations through RShiny.

10:40-11:05 Felicity Lamrock, Queen’s University Belfast

A novel approach to calculating confidence intervals for transition probabilities between health states in a cost-effectiveness model when using the R package MSM

11:05-11:20 Break.

11:20-12:40. Panel Discussion.

Opening remarks by all speakers will be followed by discussion and audience participation. Speakers include representatives from academia, government, industry, and consulting.

Francois Maignen. Principal Scientific Adviser at National Institute for Health and Care Excellence

Venediktos Kapetanakis. Principal Statistician at Evidera.

Liz Fenwick. Senior Director at Pharmerit

Andy Briggs. Professor of Health Economics at the London School of Hygiene & Tropical Medicine

12:40-13:00. Gianluca Baio, UCL.

Closing statements.